The Defence Research and Development Organisation's (DRDO) new anti-COVID drug 2-DG should work against various strains of the COVID-19 virus, DRDO chairperson Dr G Satheesh Reddy said on Monday.
"The drug 2DG developed by us should work against the various strains of the COVID-19 virus," Reddy told ANI when asked if the drug would be effective against the new strains and other mutated variants of the COVId-19 virus.
He added that the organisation was hoping to ramp up production of the drug up to one lakh sachet per day by the first week of June.
"From the first week of June, we are hoping to ramp up the production of the drug as the process to develop it takes around one month. We are hoping to increase the number of sachets production to one lakh per day," Reddy said.
The first batch of anti-COVID drug was released by Defence Minister Rajnath Singh and union health minister Harsh Vardhan on Monday.
Earlier, the Chairperson had informed that the first batch of anti-COVID drug would only be available only to AIIMS, Armed Forces Hospitals, DRDO hospitals and other places in need. It will be made available to other hospitals in June.
India on Monday reported 2,81,386 new COVID-19 cases, 3,78,741 discharges and 4,106 deaths in the last 24 hours, as per Union Health Ministry
The total cases in the country stands at 2,49,65,463, including 2,11,74,076 recoveries and 2,74,390 reported deaths. There are currently 35,16,997 active cases.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)